SSRI birth defect lawsuits are product liability and negligence claims alleging that antidepressants taken during pregnancy — Paxil, Zoloft, Prozac, Lexapro, Celexa, and the related SNRI Effexor — caused congenital malformations. The major litigations are over. GlaxoSmithKline paid more than $1 billion to settle Paxil claims, Pfizer defeated the consolidated Zoloft cases, and as of 2026 no attorneys are known to be accepting new SSRI birth defect cases.1Fierce Pharma. GSK Settles Paxil Suits for Reported $1B2Medscape. Zoloft Birth Defect Lawsuits Dismissed
Can You Still File an SSRI Birth Defect Lawsuit?
Practically speaking, the window on these cases has closed. The Paxil settlements wrapped up by 2010, the Zoloft multidistrict litigation ended in dismissal in 2016 and was affirmed on appeal in 2017, and the scattered cases involving Prozac, Lexapro, Celexa, and Effexor produced no reported large settlements or plaintiff verdicts. The FDA convened an expert panel on SSRIs and pregnancy in July 2025, but as of mid-2026 it had issued no new labeling requirements or regulatory changes that might revive the litigation.3Contemporary OB/GYN. FDA Panel Convenes on SSRIs and Pregnancy Amid Ongoing Debate Over Risk Efficacy
That does not mean every potential claim is foreclosed. State filing deadlines vary, children’s claims are often tolled, and malpractice claims against a prescribing physician run on a separate track from product liability claims against a manufacturer. If you believe a family member’s birth defect may be tied to an SSRI used during pregnancy, the right move is a prompt consultation with a product liability or medical malpractice attorney in your state, not reliance on the status of the mass litigation.
Paxil: The One Drug That Produced Real Recoveries
Paroxetine is the only SSRI the FDA has placed in pregnancy Category D, a classification reflecting positive evidence of human fetal risk.4National Center for Biotechnology Information. Selective Serotonin Reuptake Inhibitors It is also the only SSRI whose maker paid substantial money to families of children with birth defects.
In October 2009, a Philadelphia jury awarded $2.5 million to the family of Lyam Kilker, a boy born with heart defects after his mother took Paxil during pregnancy. The jury voted 10-2 that GlaxoSmithKline had negligently failed to warn of the risk and that Paxil caused the condition. It declined to award punitive damages.5The Legal Intelligencer. Paxil Verdict Documents introduced at trial showed GSK executives discussing the suppression of negative studies, and company scientists expressing alarm about rising numbers of affected children.6Community Catalyst. GSK Troubles Continue With Paxil Settlement
By July 2010, GSK had agreed to pay more than $1 billion to settle over 800 birth defect lawsuits, averaging roughly $1.2 million per family. More than 100 cases remained pending at that time. A GSK spokesperson said the company settled “despite its litigation defenses, in order to avoid the costs, burdens and uncertainties of ongoing litigation.”1Fierce Pharma. GSK Settles Paxil Suits for Reported $1B7Bloomberg. Glaxo Said to Have Paid $1 Billion to Resolve Paxil Birth Defect Lawsuits Counting earlier suicide and addiction claims, GSK’s total Paxil-related payouts exceeded $2 billion.6Community Catalyst. GSK Troubles Continue With Paxil Settlement
Zoloft: Why the Larger Litigation Collapsed
Zoloft was expected to be the next billion-dollar case. It was not. Hundreds of families alleged that sertraline, made by Pfizer, caused birth defects. Their cases were consolidated in April 2012 into MDL 2342 before Judge Cynthia M. Rufe in the Eastern District of Pennsylvania.8United States District Court for the Eastern District of Pennsylvania. MDL 2342 In Re Zoloft Products Liability Litigation
Before any bellwether trial, Pfizer challenged the plaintiffs’ experts through Daubert hearings, which test whether proposed scientific testimony meets reliability standards. In 2014, Judge Rufe excluded the plaintiffs’ initial panel of general causation experts. Plaintiffs replaced one key expert with the statistician Dr. Nicholas Jewell, tasked with establishing that Zoloft could cause cardiac defects. After a four-day hearing, Judge Rufe excluded Jewell too, finding that he selectively emphasized data supporting his conclusion, applied meta-analysis inconsistently, and failed to carry through the calculations that were supposed to form his methodology.9United States Court of Appeals for the Third Circuit. In Re Zoloft Products Liability Litigation, Third Circuit Opinion
Without admissible expert testimony to establish that Zoloft could cause birth defects at all, the plaintiffs’ steering committee conceded it could not prove general causation. Judge Rufe granted Pfizer summary judgment on April 5, 2016, dismissing more than 300 consolidated cases without a trial.2Medscape. Zoloft Birth Defect Lawsuits Dismissed The two state-court cases that had reached juries earlier, including Pesante v. Pfizer in St. Louis and a second case in Philadelphia, also went Pfizer’s way.10ClassAction.org. First Ruling in Zoloft Trial Questions Birth Defect Link The Third Circuit affirmed on June 2, 2017 in a unanimous opinion, finding no abuse of discretion in the trial judge’s gatekeeping.9United States Court of Appeals for the Third Circuit. In Re Zoloft Products Liability Litigation, Third Circuit Opinion
The Zoloft outcome explains much of why no new SSRI birth defect litigation has materialized. Proving that a specific drug caused a specific child’s defect requires expert testimony that can survive the kind of rigorous scrutiny Pfizer successfully invoked.
Prozac, Lexapro, Celexa, and Effexor
Litigation over the remaining drugs produced individual suits but no mass settlement and no reported plaintiff victory.
Eli Lilly faced Prozac claims. In Dana F. v. Eli Lilly, filed in 2013 in the Middle District of Alabama, a mother alleged her son was born in 1997 with tetralogy of Fallot and pulmonary valve insufficiency due to her Prozac use. In September 2015, Chief Judge Keith Watkins denied Lilly’s motion to dismiss, letting the plaintiff try to show that her physician would have prescribed differently with adequate warnings.11Top Class Actions. Lilly’s Motion to Dismiss Prozac Birth Defects Lawsuit Denied
Forest Laboratories faced Lexapro and Celexa claims. In Atkinson v. Forest Research Institute, a mother alleged her daughter was born in 2011 with atrioventricular canal defects and died 24 days later; Judge Robert Kugler of the District of New Jersey declined to dismiss the case in June 2014.12Courthouse News Service. Fatal Birth Defects May Leave Drugmaker Liable Twelve additional lawsuits were filed in West Virginia’s Cabell Circuit Court in 2015, alleging Forest knew of birth defect risks through pre- and post-market studies yet continued to market the drugs as safe for women of childbearing age.13Legal Newsline. 12 Cabell Co. Lawsuits Blame Lexapro for Birth Defects
Effexor, technically an SNRI, was swept into the same wave. Cases were consolidated into MDL 2458 in the Eastern District of Pennsylvania, also before Judge Rufe. At least 46 cases were pending by late 2013, with claims paralleling the SSRI allegations: heart defects, persistent pulmonary hypertension, omphalocele, and craniosynostosis. By early 2015, plaintiffs’ counsel asked to dismiss 26 of the 68 then-pending cases.14Top Class Actions. Missouri Couple Sue Pharmaceutical Giants Over Son’s Birth Defects
Suing the Prescribing Doctor Instead
A separate path targets the physician who prescribed the drug rather than the company that made it. Medical malpractice claims argue that a doctor deviated from the standard of care by prescribing a drug with known teratogenic risks to a pregnant patient without adequate justification or informed consent. These cases avoid the “learned intermediary” doctrine that shields manufacturers whose warnings to prescribers are deemed adequate.15Journal of the American Academy of Psychiatry and the Law. Perinatal Psychopharmacology Litigation
The most notable malpractice recovery involved Depakote, an anticonvulsant rather than an SSRI, but it illustrates how these claims can succeed where product liability fails. In Muhammad v. Northwestern Memorial Hospital, filed in Cook County, Illinois, the family alleged that doctors prescribed Depakote to Charles Muhammad’s mother despite knowing its teratogenic risks. Charles was born in 2006 with spina bifida, fluid buildup in the brain, and other permanent impairments; by age 12, he had the mental capacity of a five- or six-year-old. In September 2018, a jury awarded $18.5 million, later reduced to $12 million under a pre-trial high-low agreement.16Orlando Sentinel. Northwestern Memorial Hit With $18.5 Million Verdict in Case of Boy Born With Disabilities17Illinois Courts. Muhammad v. Abbott Laboratories, Illinois Supreme Court
Courts have generally recognized a distinction between “acts of commission” (actively prescribing a contraindicated drug) and “acts of omission” (failing to prescribe or discontinuing treatment). Claims built on active prescribing decisions tend to be more successful because the causal chain is more direct.15Journal of the American Academy of Psychiatry and the Law. Perinatal Psychopharmacology Litigation
Filing Deadlines Vary by State
If any claim remains viable, timing is the first hurdle. Deadlines vary significantly by state, by the type of claim, and by whether the defendant is a manufacturer or a prescriber. Product liability claims against drug companies and medical malpractice claims against doctors often run on different clocks.
Two doctrines can help. The “discovery rule” can delay the start of the limitations period until the injury is discovered or reasonably should have been discovered, which matters when a birth defect’s link to a medication is not immediately apparent. “Tolling for minors” can pause or extend the deadline because children cannot file lawsuits on their own behalf. A “statute of repose,” however, can override both of these protections and impose a hard cutoff regardless of when the connection was discovered or how old the child is. These rules are state-specific and fact-dependent, which is why early legal consultation matters even in a litigation landscape that otherwise looks closed.
The Science Is Still Contested
The medical debate that drove this litigation has not been resolved. A National Birth Defects Prevention Study analysis published in the New England Journal of Medicine in 2007 found statistically significant associations between early-pregnancy SSRI use and three specific defects — anencephaly, craniosynostosis, and omphalocele — though its authors cautioned that absolute risks were small and some findings could reflect chance.18New England Journal of Medicine. Use of Selective Serotonin-Reuptake Inhibitors During Pregnancy and Risk of Birth Defects A 2021 review concluded that SSRIs as a class were associated with a 30% to 130% increase in the risk of major congenital malformations, with cardiac defects elevated by at least 60%.19National Center for Biotechnology Information. Selective Serotonin Reuptake Inhibitors and Congenital Malformations: A Review Many clinicians counter that untreated maternal depression itself carries serious risks, including preterm delivery, preeclampsia, and suicide, and that separating the drug’s effects from the illness’s has always been the central methodological problem.20STAT News. SSRI Drugs FDA Review Panel Antidepressants Pregnancy
The FDA panel in July 2025 heard sharply divided testimony. Some panelists called for stronger warnings, including a boxed warning on maternal and fetal complications; others argued that controlled analyses show similar outcomes between SSRI use and untreated depression.21Regulatory Affairs Professionals Society. FDA Panel Debates Label Change on SSRI Use During Pregnancy No regulatory action has followed. Unless that changes, the SSRI birth defect litigation story is one that ended with Paxil’s $1 billion settlements and Zoloft’s dismissal, with scattered individual cases and malpractice claims as the only remaining avenues for families.